Screening for Type 2 Diabetes by Oral Glucose Tolerance Test in the Population Groups Not Diagnosed by Fasting Blood Glucose in Guadeloupe

In France, only the fasting blood glucose (FBG) measurement is recommended for diabetes screening. Ethnic heterogeneity and genetic polymorphisms specific to the Afro-Caribbean and Indo-Caribbean population in Guadeloupe justify the interest to early screen type 2 diabetes mellitus (T2DM). Our main objective is to estimate the prevalence of T2DM defined by oral glucose tolerance (OGTT) in subjects with risk factors for T2DM and not diagnosed with the FBG.

NCT Number	NCT07233434
Lead Sponsor	Centre Hospitalier Universitaire de la Guadeloupe
Conditions	Non-Diabetic
Enrollment	120 participants
Start Date	2021-02-02
Primary Completion	2027-02-02 (estimated)
Study Completion	2028-08-02 (estimated)
Updated on ClinicalTrials.gov	2025-11-18